Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al.
Riksen
Niels P
NP
Rongen
Gerard A
GA
Smits
Paul
P
van Riel
Piet
P
Barrera
Pilar
P
D000659:AMP Deaminase / Q000235:genetics* / Q000378:metabolism; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D004351:Drug Resistance / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D018482:Muscle, Skeletal / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D000659:AMP Deaminase; C514117:AMPD1 protein, human; D008727:Methotrexate